ORKA-002

Oruka Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	ORKA-002
Sponsor	Oruka Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis (PHASE2)
ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ORKA-002 CI brief — competitive landscape report
ORKA-002 updates RSS · CI watch RSS
Oruka Therapeutics, Inc. portfolio CI